...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Women s Health >Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study
【24h】

Effect of ultramicronized-palmitoylethanolamide and co-micronized palmitoylethanolamide/polydatin on chronic pelvic pain and quality of life in endometriosis patients: An open-label pilot study

机译：超微粉化棕榈酰乙醇酰胺和超微粉化棕榈酰乙醇酰胺/多肽对子宫内膜异位症患者慢性盆腔疼痛和生活质量的影响：一项开放性试验研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: The aim of the present study was to evaluate the effectiveness of the ultramicronized-palmitoylethanolamide (um-PEA) and co-micronised palmitoylethanolamide/polydatin m(PEA/PLD) in the management of chronic pelvic pain related to endometriosis in patients desiring pregnancy. Patients and methods: Thirty symptomatic women with laparoscopic diagnosis of endometriosis and pregnancy desire were enrolled. Patients were treated with um-PEA twice daily for 10 days followed by m(PEA/PLD) twice daily for 80 days. Intensity of chronic pelvic pain, dyspareunia, dysmenorrhea, dyschezia, and dysuria were evaluated at baseline, after 10, 30, 60, 90 days and after 30 days from the end of treatment, by VAS. Quality of life and women’s psychological well-being were evaluated at baseline and at the end of the treatment after 90 days with 36-Item Short Form Health Survey questionnaire and Symptom Check list-90 questionnaire, respectively. All collected data were analyzed with the non-parametric Wilcoxon test. Results: At the end of the treatment, all patients showed a significant improvement in chronic pelvic pain, deep dyspareunia, dysmenorrhea, dyschezia, as well as in quality of life and psychological well-being. Conclusion: In spite of the study’s limited sample size and the open-label design, this research suggests the efficacy of um-PEA and m(PEA/PLD) in reducing painful symptomatology and improving quality of life as well as psychological well-being in patients suffering from endometriosis. Additionally, this treatment did not show any serious side effect, proving particularly suitable for women with pregnancy desire and without other infertility factors.
机译：目的：本研究的目的是评估超微粉化的棕榈酰乙醇酰胺（um-PEA）和微粉化的棕榈酰乙醇酰胺/多聚体素m（PEA / PLD）在治疗与子宫内膜异位症相关的慢性盆腔痛的患者中的有效性。患者和方法：招募了30例经腹腔镜检查诊断为子宫内膜异位和妊娠愿望的有症状妇女。患者每天两次用um-PEA治疗10天，然后每天两次用m（PEA / PLD）治疗80天。在基线后，治疗结束后10、30、60、90天和30天后，通过VAS评估慢性骨盆疼痛，痛经，痛经，性交困难和排尿困难的强度。在90天后的基线和治疗结束时，分别使用36项简易健康调查问卷和Symptom Check list-90问卷评估了生活质量和妇女的心理健康。使用非参数Wilcoxon检验分析所有收集的数据。结果：在治疗结束时，所有患者的慢性骨盆痛，深度性痛经，痛经，精神分裂症以及生活质量和心理健康均显着改善。结论：尽管该研究的样本量有限且采用开放标签设计，但该研究表明um-PEA和m（PEA / PLD）在减轻疼痛症状，改善生活质量和心理健康方面的功效。患有子宫内膜异位的患者。此外，这种治疗方法未显示任何严重的副作用，事实证明该方法特别适用于有妊娠愿望且没有其他不育因素的女性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号